Unifying Model of Alzheimer’s Disease Proposed
Scientists have proposed a unifying explanation for Alzheimer's disease, linking widespread gene disruption to chronic stress granules.
Scientists have proposed a unifying explanation for Alzheimer's disease, linking widespread gene disruption to chronic stress granules.
This episode of Clinical Lab Chat covers the how and why of making precise clinical diagnosis of neurodegenerative diseases.
A new capillary blood test offers a simple, mail-in method to detect Alzheimer’s biomarkers, paving the way for accessible global testing.
Scientists have validated a blood test platform that measures over 100 biomarkers related to Alzheimer’s disease.
Read MoreThe time of day significantly affects Alzheimer’s biomarkers, highlighting the need for standardized blood sampling times.
Read MoreRevvity’s APOE assay allows for precise APOE genotyping to assess patient risks before starting anti-amyloid therapy for Alzheimer’s disease.
Read MoreThe Alzheimer’s Drug Discovery Foundation invested $7 million in C2N Diagnostics to advance the development of Alzheimer’s blood biomarkers.
Read MoreFujirebio Diagnostics, Inc. has submitted its Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test to the FDA.
Read MoreBlood-based microRNA biomarkers can predict the progression of Alzheimer’s disease, offering a less invasive method for early diagnosis.
Read MoreMount Sinai Health System will deploy blood-based biomarkers for early Alzheimer’s and dementia detection.
Read MoreApollo Health’s BrainScan test detects early signs of Alzheimer’s and neurodegenerative diseases through a non-invasive blood test.
Read MoreThe plasmonic biosensor is capable of detecting dopamine from blood, offering a tool for screening cancers and neurological conditions.
Read MoreResearchers developed a blood test that analyzes potassium isotopes, offering a potential method for diagnosing Alzheimer’s disease earlier.
Read MoreThe FDA has endorsed the use of Amprion’s alpha-synuclein seed amplification assay for detection of neurodegenerative diseases.
Read MoreNew research highlights the use of epigenetic markers to better understand and predict dementia risk, including Alzheimer’s disease.
Read MoreCLP interviewed Alessio Travaglia, PhD, PMP, director, Translational Science, Neuroscience, at the FNIH, to discuss all aspects of Alzheimer’s testing and treatment.
Read MoreGenova Diagnostics’ Alzheimer’s Assessment solution is a non-invasive blood test using the p-Tau217 biomarker for early Alzheimer’s detection.
Read MoreProteins associated with comorbid Alzheimer’s pathology in Parkinson’s dementia and dementia with Lewy bodies develop after the onset of the disease.
Read More